Teva Pharmaceuticals has entered into a definitive agreement to acquire Emalex Biosciences, strengthening its neuroscience pipeline through the addition of ecopipam, a late-stage investigational treatment for pediatric Tourette syndrome. The move reinforces the company’s strategic shift toward innovation-led expansion, with ecopipam positioned as a registration-ready, first-in-class selective dopamine D1 receptor antagonist. The asset has already secured FDA Orphan Drug and Fast Track designations, and following positive Phase 3 results demonstrating statistically significant outcomes on the primary efficacy endpoint, an NDA submission is expected in the second half of 2026. This Emalex Acquisition is aligned with Teva’s focus on advancing high-value therapies in specialized areas of unmet clinical need.
Under the terms of the agreement, Teva will make an upfront payment of $700 million to Emalex shareholders, with the potential for an additional $200 million tied to commercial milestones, alongside royalties based on global net sales of ecopipam, subject to regulatory approvals. Commenting on the deal, Richard Francis, President and Chief Executive Officer of Teva, stated, “This is a prime example of our Pivot to Growth strategy in action, advancing focused, capital-efficient agreements that expand our late-stage innovative pipeline and commercial portfolio, while delivering on our unrelenting commitment to patients.” He added, “There is a real unmet need in Tourette syndrome, and families deserve additional options that can help manage symptoms while minimizing side effects. With our deep neuroscience expertise, we are well-positioned to advance this first-in-class investigational compound.” The Emalex Acquisition is expected to support both near-term portfolio expansion and longer-term growth objectives.
Ecopipam represents a differentiated approach in Tourette syndrome treatment, as currently approved therapies primarily target dopamine D2 receptors, whereas ecopipam selectively acts on D1 receptors. Eric Messner, Chief Executive Officer of Emalex, said, “This moment reflects years of focused work to advance a first-in-class therapy for patients with Tourette syndrome who need better options. I’m deeply grateful to the Emalex team for the rigor and urgency they’ve brought to this program, and to the patients, families, and investigators who made this progress possible. Teva’s global scale and neuroscience leadership position will help ecopipam reach patients as quickly and broadly as possible, which is our goal.” The company was originally founded by Paragon Biosciences, which focuses on building biology-based ventures.
Jeff Aronin, CEO of Paragon Biosciences and Chairman of Emalex, emphasized the development pathway, stating, “We built Emalex around a clear patient need and advanced ecopipam to late-stage readiness with speed and precision. At Paragon, we take companies with proven science and a clear path to patients, then choose the fastest way to reach them. Teva brings the scale and neuroscience expertise to execute globally and accelerate access for patients.” The transaction remains subject to customary closing conditions, including regulatory approvals, and is expected to be completed by the third quarter of 2026. Teva plans to finance the upfront component using existing cash reserves while maintaining its financial targets for 2027.
